美股异动丨诺和诺德一度涨近5%，礼来减肥药片试验结果不及预期

Core Viewpoint - Novo Nordisk's stock rose nearly 5% to $51.08 as its weight loss drug Wegovy outperformed Eli Lilly's experimental weight loss pill orforglipron, which showed less effective results in clinical trials [1] Company Summary - Eli Lilly's recent study revealed that its experimental GLP-1 pill, orforglipron, resulted in an average weight loss of 12.4% after 72 weeks, compared to a 0.9% weight loss in the placebo group among over 3,000 participants [1] - Eli Lilly has marketed orforglipron as a cheaper alternative to popular obesity injections like Zepbound and Novo Nordisk's Wegovy, which are currently leading the obesity drug market [1] - Analysts had previously expected orforglipron to achieve a weight loss of 14.9% over 68 weeks, based on data from a 2021 trial, with some even believing it could surpass Wegovy's effectiveness [1] Industry Summary - The obesity drug market is projected to grow to $150 billion in the early part of the next decade, highlighting significant growth potential in this sector [1]